Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: NIL: NA
Control Intervention1: NIL: NA
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Patient of locally advanced non small cell lung cancer who will be treated with concurrent chemoradiation (EBRT 60Gy/30frs/6weeks along with Platinum doublet based chemotherapy) or sequential chemoradiation(3-4 cycles of Platinum doublet based chemotherapy followed by EBRT 55Gy/20Frs/4weeks) or radical radiotherapy alone (EBRT 55Gy/20Frs/4weeks) All patients who will be receiving Intensity modulated radiotherapy (IMRT) with daily image guidance
Exclusion criteria
Exclusion criteria: Post operative radiotherapy Palliative radiotherapy Stereotactic body radiotherapy (SBRT) for early NSCLC Reirradiation Radiotherapy for small cell lung cancer Patients who will receive 3D conformal radiotherapy (3DCRT) for NSCLC Consolidative radiotherapy for oligometastatic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rates of & time to develop patient reported acute moderate to severe difficulty in swallowing in patients treated with concurrent chemoradiotherapy sequential chemoradiotherapy or radical radiotherapy alone in locally advanced non small cell lung cancer Timepoint: During radiotherapy & within 3 months of radiotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| To find out the concordance in grades & time to develop patient reported vs clinician reported acute radiation esophagitis To find out the factors (patient related/tumour related or treatment related) that are associated with development of patient reported acute moderate to severe difficulty in swallowing Timepoint: During radiotherapy & within 3 months of radiotherapy | — |
Countries
India
Contacts
Public ContactDr Arshmeen Kaur
Tata Medical Centre
Outcome results
None listed